References

1. P. van der Brüggen, C. Traversari, P.Chomez, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647, (1991).

2. D. Nagorsen, C. Scheibenbogen, F.M. Marincola, et al. Natural T cell immunity against cancer. Clin Cancer Res 9, 4296-4303 (2003).

3. R.M. Steinmann., H. Hemmi. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311, 17-58 (2006).

4. H. Wagner. Endogenous TLR ligands and autoimmunity. Adv Immunol 91,159-173 (2006).

5. P.D. Lee, C. Yee, P.A. Savage, et al. Charcterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med 5, 677-685 (1999).

6. K. Khazaie, S. Prifti, P. Beckhove, A. Griesbach, S. Russell, M. Collins, V. Schirrmacher. Persistence of dormant tumor-cells in the bone marrow of tumor-cell-vaccinated mice correlates with long term immunological protection. Proc Natl Acad Sci 91, 7430-7434 (1994).

7. M. Müller, F. Gounari, S. Prifti, H.J. Hacker, V. Schirrmacher, K. Khazaie. EblacZ tumor dormancy in bone marrow and lymph nodes: active control at proliferating tumor cells by CD8+ immune T cells. Cancer Res 58, 5439-5446 (1998).

8. M. Feuerer, P. Beckhove, L. Bai, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 4, 452-458 (2001).

9. J. Müller-Berghaus, K. Ehlert, S. Ugurel, V. Umansky, V. Schirrmacher, P. Beckhove, D. Schadendorf. Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage. Cancer Res 66(12), 5997-6001 (2006).

10. F. Schmitz-Winnenthal, C. Volk, K. Z'graggen, L. Galindo, D. Nummer, Y. Ziouta, M. Bucur, J. Weitz, V. Schirrmacher, M.W. Büchler, P. Beckhove. High frequencies of functional tumor-reactive T cells in bone marrow and blood marrow and blood of pancreatic cancer patients. Cancer Res 65(21), 10079-10087 (2005).

11. F.H. Schmitz-Winnenthal, L.V. Galindo Escobedo, P. Beckhove, V. Schirrmacher, M. Bucur, Y. Ziouta, C. Volk, B. Schmied, M. Koch, D. Antolovic, J. Weitz, M.W. Büchler, K. Z'graggen. Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon gamma. Int J Oncol 28(6), 1419-1428 (2006).

12. C. Choi, M. Witzens, M. Bucur, M. Feuerer, N. Sommerfeldt, A. Trojan, A. Ho, V. Schirrmacher, H. Goldschmidt, P. Beckhove. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of multiple myeloma patients. Blood 105(5), 2132-2134 (2005).

13. P. Beckhove, M. Feuerer, M. Dolenc, F. Schuetz, C. Choi, N. Sommerfeldt, J. Schwendemann, K. Ehlert, P. Altevogt, G. Bastert, V. Schirrmacher, V. Umansky. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autolgous tumors. J Clin Invest 114, 67-76 (2004).

14. N. Sommerfeldt, F. Schütz, C. Sohn, J. Förster, V. Schirrmacher, P. Beckhove. The shaping of a polyvalent and highly individual T cell repertoire in the bone marrow of breast cancer patients.Cancer Res 66(16), 8258-2365 (2006).

15. M. Feuerer, P. Beckhove, N. Garbi, Y. Mahnke, A. Limmer, M. Hommel, G.J., Hämmerling, B. Kyewski, A. Hamann, V. Umansky, V. Schirrmacher. Bone marrow as a priming site for T cell responses to blood-borne antigen. Nat Med 9, 1151-1157 (2003).

16. L.L. Cavanagh, R. Bonasio, I.B. Mazo, et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat Immunol 10, 1029-1037 (2005).

17. Y.D.Mahnke, J. Schwendemann, P. Beckhove, V. Schirrmacher. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumor cells. Immunology 115, 325-336 (2005).

18. K. Noonan, W. Matsui, P. Serafini, et al. Activated marrow infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 65, 2026-2034 (2005).

19. S. Braun, F.D. Vogl, B. Naume, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353, 793-802 (2005).

20. V. Schirrmacher. T-cell immunity in the induction and maintenance of a tumor dormant state. Sem Cancer Biol 11, 285 (2001).

21. L. Bai, P. Beckhove, M. Feuerer, V. Umansky, C. Choi, E.F. Solomayer, I.J. Diel, V. Schirrmacher, Cognate interactions between memory T cells and tumor antigen presenting dendritic cells from bone marrow of breast cancer patients: bi-directional cell stimulation survival and anti-tumor activity in vivo. Int J Cancer 103, 73-83 (2003).

22. G. Angelini, S. Gardella, M. Ardy, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. PNAS 99, 14911496 (2002).

23. D. Nagorsen, C. Scheibenbogen, A. Letsch, et al. T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. J Transl Med 3, 3 (2005).

24. P.G. Fournier, J.M. Chirgwin, T.A. Guise. New insights into the vicious circle of bone metastases. Curr Opin Rheumatol 18, 396-404 (2006).

25. R. Ganss, E. Ryschisch, E. Klar, et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62, 1462-1470 (2002).

26. M. M. Berger, G. Bergers, B. Arnold, et al. Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. B Blood 105, 1094-1101 (2005).

27. Q. Q. Le, H. Cao, D. Nelson, et al. Galectin -1:A link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23, 8932-8941 (2005).

28. Y. Kawakami, N. Dang, X. Wang, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumour-infiltrating lymphocytes from 123 patients with melanoma. J Immunother 23, 17-27 (2000).

29. H. H. Benlalam, N. Labarriere, B. Linard, et al. Comprehensive analysis of the frequency of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy. Eur J Immunol 31, 2007-2015 (2001).

30. P.P.F. Robbins, M. El-Gamil, Y.F. Li, et al. Multiple HLA-II-restricted melanocyte differentiation antigens are recognized by tumour-infiltrating lymphocytes from a patient with melanoma. J Immunol 169, 6036-6047 (2002).

31. S. Seiter, V. Monsurro, M.B. Nielsen, et al. Frequency of MART-1/MelanA and gp100/ PMel17-specific T cells in tumnor metastases and cultured tumour-infiltrating lymphocytes. J Immunother 25, 252-263 (2002).

32. M.M.T. Spiotto, H. Schreiber. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer specific antigens cross-presented by stromal cells. Cancer Immun 5, 8

33. K.K. Hayashi, K. Yonamine, K. Masuko-Hongo, et al. Clonal expansion of T cells that are specific for autologous ovarian tumour among tumour-infiltrating T cells in humans. Gynecol Oncol 74, 86-92 (1999).

34. M. Koch, P. Beckhove, J. op den Winkel, et al. Tumor infiltrating T-lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg 244, 986-992

35. J.J. Galon, A. Costes, F. Sanchez-Cabo, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).

36. F.F. Pages, A. Berger, M. Camus, et al. Effector memory T cells, early metastasis and survival in colorectal cancer. N Eng J Med 353, 2654-2666 (2005).

37. T.T. Alvaro, M. Lejeune, M-T. Salvado, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. JCO 24, 5350-5357 (2006).

38. X.X. Yan, R. Orentas, B. Johnson. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine 33, 188-198 (2006).

39. E. Sato, S.H. Olson, J. Ahn, et al. Intraepithelial CD8 TIL and a high CD8+ /regulatory T cell ratio are associated with a favourable prognosis in ovarian cancer. PNAS 102, 18538-18543

40. Y.Y. Xu, S.H. Kroft, R.W. McKenna, et al. Prognostic significance of tumour infiltrating T lymphocytes and T cell subsets in de novo diffuse large B cell lymphoma: a multiparameter flow cytometry study. Br J Haematol 112, 945-949 (2001).

41. J.B. Haanen, A. Baars, R. Gomez, et al. Melanoma specific TIL but not circulating melanoma specific TIL predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 55, 451-458 (2006).

42. J. Herbert III Zeh, T. Michale Lotze. Addicted to death: Invasive cancer and the immune response to unscheduled cell death. J Immunotherapy 28(1), 1-9 (2005).

43. N. Sommerfeldt, P. Beckhove, Y. Ge, et al. Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 66, 7716-7723 (2006).

44. M.R. Shurin, G.V. Shurin, A. Lokshin, et al. Intratumoral cytokines, chemokines/growth factors and tumour infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 25, 333-356 (2006).

45. D.R. Roach, A.G.D. Bean, C. Demangel, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation and clearance of mycobacterial infection. J Immunol 168, 4620-4627 (2002).

46. L. Broderick, R.B. Bankert. Memory T cells in human tumor and chronic inflammatory microenvironments: sleeping beauties re-awakened by a cytokine kiss. Immunol Invest 35, 419-436

47. F. De Paola, R. Ridolfi, A. Riccobon, et al. Restored T cell activation mechanisms in human tumour infiltrating lymphocytes and colorectal carcinomas after exposure to interleukin-2. Br J Cancer 88, 320-326 (2003).

48. S.S. Radoja, M. Saio, D. Schaer, et al. CD8+ tumour infiltrating T cells are deficient in per-forin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol 167, 5042-5051 (2001).

49. T.T.F. Gajewski, Y. Meng, C. Blank, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213, 131-145 (2006).

50. X.X. Yan, R.J. Orentas, B.D. Johnson. Tumor-derived migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine 33, 188-198 (2006).

51. A.A.G. Jarnicki, J. Lysaght, S. Todryk, et al. Suppression of antitumor immunity by IL-10 and TGFß producing T cell infiltrating the growing tumour: influence of tumour microenvironment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177, 896-904 (2006).

52. Y. Luo, H. Zhou, J. Krueger, et al. Targeting tumor-associated macrophages as a novel strategy against breast cacner. JCI116, 2132-2141(2006).

53. L. Broderick, S. Yokota, J. Reineke, et al. Human CD4 effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-y and eradicate tumor cells. J Immunol 174, 898-906 (2005).

54. L.O. Broderick, S.P. Brooks, H. Takita, et al. IL-12 reverses anergy to T cell receptor triggering in human lung tumour-associated memory T cells. Clin Immunol 118, 159-169 (2006).

55. Y.W. Hsiao, K.W. Liao, S.W. Hung, et al. Tumour infiltrating lymphocytes secretion of IL-6 antagonizes tumour-derived TGFß1 and restores the lymphokine-activated killing activity. J Immunol 172, 1508-1514 (2004).

56. F.M. Marincola, E. Wang, M. Herlyn, B. Seliger, S. Ferrone. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 24, 335-342 (2003).

57. V. Monsurro, E. Wang, M.C. Panelli, D. Nagorsen, P. Jin, Z. Katia, et al. Active-specific immunization against melanoma: is the problem at the receiving end? Semin Biol 13, 473-480 (2003).

58. A.B. Frey, Monu Ngozi. Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J Leukoc Biol 79, 652-662 (2006).

59. L. Burdelaya, et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 174, 3925-3931 (2005).

60. J.J. Kobie, R.S. Wu, R.A. Kurt, et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63, 18601864 (2003).

61. B. Washburn, V. Schirrmacher. Human tumor cell infection by Newcastle Disease Virus leads up to upregulation of HLA and cell adhesion molecules and to induction of interferons, chem-okines and finally apoptosis. Int J Oncol 21, 85-93 (2002).

62. C. Ertel, N.S. Millar, P.T. Emmerson, V. Schirmracher, P. von Hoegen. Viral hemagglutinin augments peptide specific cytotoxic T-cell responses. Eur J Immunol 23, 2592 (1993).

63. C. Haas, C. Ertel, R. Gerhards, V. Schirrmacher. Introduction of adhesive and costimulatory immune functions into tumor cells by inflection with Newcastle disease virus. Int J Oncol 13, 1105 (1998).

64. C.C. Termeer, V. Schirrmacher, E.B. Bröcker, J.C. Becker. Newcastle disease virus infection induces B7-1/B7-2 independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 7, 316 (2000).

65. V. Schirrmacher. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved anti-tumor immune memory. Cancer Immunol. Immunother 54(6) (Apr.), 587-598 (2005).

66. P. Yu, Y. Lee, W. Liu, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5, 141-149 (2004).

67. B. Aggarwal. Signalling pathways of the TNF superfamily: a double edged sword. Nat Rev Immunol 3, 745-756 (2003).

68. G. Dranoff. GM-CSF-secreting melanoma vaccines. Oncogene 22, 3188-3192 (2003).

69. L.M. Liau, R.M. Prins, S.M. Kiertscher, S.K. Odesa, T.J. Kremen, A.J. Giovannone, J.W. Lin, D.J. Chute, P.S. Mischel, T.F. Cloughesy, M.D. Roth. Dendritic cell vaccination in glioblast-oma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11(15), 5515-5525 (2005).

70. Y. Peng, Y. Laouar, M.O. Li, E.A. Green, R.A. Flavell. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA 101, 4572-4577 (2004).

71. L. Gorelik, R.A Flavell. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signalling in T cells. Nat Med 7, 1118-1122 (2001).

72. C.-P. Mao, C.-F. Hung, T.-C. Wu. Immunotherapeutic strategies employing RNA interference technology for the control of cancers. J Biomedical Science DOI 10.1007/s11373-006-9131-5 (2006).

73. S. Sakaguchi. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22, 531-562 (2004)

74. M.J. Turk, J.A. Guevara-Patino, G.A. Rizzuto, M.E. Engelhorn, S. Sakaguchi, A.N. Houghton. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200, 771-782 (2004).

75. F.M. Foss. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Ann NY Acad Sci 941, 166-176 (2001).

76. J. Dannull, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115, 3623-3633 (2005).

77. I. Lee, L. Wang, A.D. Wells, M.E. Dorf, E. Ozkaynak, W.W. Hancock. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 201, 1037-1044 (2005).

78. V.A. Boussiotis, et al. Prevention of T cell anergy by signalling through the gamma c chain of the IL-2 receptor. Science 266, 1039-1042 (1994).

79. R.M. Teague, et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 12, 335-341 (2006).

80. H.L. Kaufman, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 115, 1903-1912 (2005).

81. H.L. Kaufmann, S. Cohen, K. Cheung, G. DeRaffele, J. Mitcham, D. Moroziewicz, J. Schlom, C. Hesdorffer. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther 17(2), 239-244 (2006).

82. H.L. Kaufman, G. DeRaffele, J. Divito, H. Horig, D. Lee, D. Panicali, M. Voulo. A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma. Hum Gene Ther 12(11), 1459-1480 (2001).

83. C. Haas, M. Lulei, P. Fournier, A. Arnold, V. Schirrmacher. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine 23, 2439-2453 (2005).

84. C. Haas, M. Lulei, P. Fournier, A. Arnold, V. Schirrmacher. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable anti-tumor activity in human lymphocytes. Int J Cancer 118(3) (Mar 1), 658-667 (2005).

85. G.G. Parmiani, C. Castelli, P. Dalerba, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94, 805-818 (2002).

86. G.G. Zeng, Y. Li, M. El-Gamil, et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 62, 3630-3535 (2002).

87. Y.Y. Kawarada, R. Ganss, N. Garbi, T. Sacher, B. Arnold, G.J. Hämmerling. NK and CD8+ T cell mediated eradication of established tumors by peritumoral injections of CpG-oligode-oxynucleotides. J Immunol 167, 5247-5253 (2001).

88. C.C. Fiola, B. Peeters, P. Fournier, A. Arnold, M. Bucur, V. Schirrmacher. Tumor selective replication of Newcastle Disease Virus: Association with defects of tumor cells in antiviral defence. Int J Cancer 119, 328-338 (2006).

89. P.P. Fournier, J. Zeng, V. Schirrmacher. Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-a responses by viral protein or dsRNA. Int J Oncol 23, 673-680 (2003).

90. A.A. Pichlmair, O. Schulz, C.P. Tan, T.I. Näslund, P. Liljeström, Weber Friedemann, C. Reis e Sousa. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5 -phosphates. Science 314, 997-1001 (2006).

91. D.D. Stetson, R. Metzhitov. Type I interferons in host defense. Immunity 25, 373-381 (2006).

92. M.M. Mohty, A. Viall-Castellano, J.A. Nunes, D. Isnardon, D. Olive, B. Gaugler. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J Immunol 171(7), 3385-3393 (2003).

93. M.M.T. Spiotto, H. Schreiber. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun 5, 8 (2005).

94. B.B. Zhang, N.A. Bowerman, J.K. Salama, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204, 49-55 (2007).

95. S.S. Nair, D. Boczkowski, B. Moeller, M. Dewhirst, J. Vieweg, E. Gilboa. Synergy between tumor immunotherapy and anti-angiogenic therapy. Blood 102, 964-971 (2003).

96. T.T. Kelly. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signalling and are potential targets for cancer therapy. Drug Resist Updat 8, 51-58 (2005).

97. S.S. Mocellin, C.R. Rossi, D. Nitti. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp Cell Res 299, 267-278 (2004).

98. C.C. Uyttenhove, et al. Evidence for a tumoral immune resistance mechanism based on tryp-tophan degradation by indoleamine 2, 3 dioxygenase. Nat Med 9, 1269-1274 (2003).

99. P.P.C. Rodriguez, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64, 5839-5849 (2004).

100. B.B. Ahn, H. Ohshima. Suppression of intestinal polyposis in Apc (Min/+) mice by inhibiting nitric oxide production. Cancer Res 61, 8357-8360 (2001).

101. S.S.S. Agarwala, M.H. Sabbagh. Histamine dihydrochloride: inhibiting oxidants and syner-gising IL-2 mediated immune activation in the tumor microenvironment. Expert Opin Biol Ther 1, 869-879 (2001).

102. C.C. Peyssonnaux, R.S. Johnson. An Unexpected Role for Hypoxic Response.Cell Cycle 3, 168-171 (2004).

103. V.V. Bocci, A. Larini, V. Micheli. Restoration of normoxia by ozone therapy may control neoplastic growth: a review and a working hypothesis. J Altern Complement Med 11(2), 257-265 (2005).

104. N.N. Senzer, S. Mani, A. Rosemurgy, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 22, 592-601 (2004).

105. J.J.L. Gulley, P.M. Arlen, N. Bastian, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11, 3353-3362 (2005).

106. C.C. Lurquin, B. Lethe, E. DePlaen, et al. Constrasting frequencies of antitumor and antivaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201, 249-257 (2005).

107. S.S. Demaria, N. Bhardwaj, W.H. McBride, S.C. Formenti. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiation Oncology Biol Phys 63(3), 655-666 (2005).

108. E.E. Vorothnikova, R. Ivkov, A. Foreman, M. Tries, S.J. Braunhut. The magnitude and time-dependence of the apoptotic response of normal and malignant cells subjected to ionizing radiation versus hyperthermia. Int J Radiat Biol 82, 549-559 (2006).

109. Q.Q. Chen, DT Fisher, K.A. Clancy, J.M. Gauguet, W.C. Wang, E. Unger, S. Rose-John, U.H. von Andrian, H. Baumann, S.S. Evans. Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol 7(12), 1299-1308 (2006).

110. B.B. Tang, L. Li, Z. Jiang, Y. Luan, D. Li, W. Zhang, E. Reed, Q.Q. Li. Characterization of the mechanisms of electrochemotherapy in an in vitro model for human cervical cancer. Int J Oncol 26(3), 703-711 (2005).

111. Y.Y. Xin, F. Xue, B. Ge, F. Zhao, B. Shi, W. Zhang. Electrochemical treatment of lung cancer, Bioelectromagnetics 18, 8-13 (1997).

112. A.A. Loskog, H. Dzojic, S. Vikman, C. Ninalga, M. Essand, O. Korsgren, T.H. Totterman. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol 172, 7200-7205 (2004).

113. I.I. Van Bruggen, D.J. Nelson, A.J. Currie, C. Jackaman, B.W.S. Robinson. Intratumoral Poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model. J Immunother 28, 359-367 (2005).

114. T.T.R. Sana, M.J. Janatpour, M. Sathe, L.M. McEvoy, T.K. McClanahan. Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. Cytokine 29, 256-269 (2005).

115. T.T. Lichtor, R.P. Glick. Cytokine immuno-gene therapy for treatment of brain tumors. J Neuro-Oncol 65, 247-259 (2003).

116. E.E. Wang, L.D. Miller, G.A. Ohnmacht, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62, 3381-3386 (2002).

0 0

Post a comment